Selecta Biosciences, Inc.
NASDAQ:SELB
1.16 (USD) • At close November 21, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Selecta Biosciences, Inc. |
Symbool | SELB |
Munteenheid | USD |
Prijs | 0.881 |
Beurswaarde | 135,200,754 |
Dividendpercentage | 0% |
52-weken bereik | 0.785 - 1.99 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Carsten Brunn Ph.D. |
Website | https://selectabio.com |
An error occurred while fetching data.
Over Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)